Addition of Vectibix™ to Avastin® plus Chemotherapy Does Not Improve Outcomes for Metastatic Colorectal Cancer

Addition of Vectibix™ to Avastin® plus Chemotherapy Does Not Improve Outcomes for Metastatic Colorectal Cancer

According to results presented at the 9th World Congress on Gastrointestinal Cancer, the addition of Vectibix™ (panitumumab) to Avastin® (bevacizumab) and the chemotherapy regimens FOLFOX or FOLFIRI does not improve outcomes for patients with metastatic colorectal cancer.

Colorectal cancer remains the second leading cause of cancer-related deaths in the United States. Most patients succumb to the cancer when it is in advanced stages. Metastatic colorectal cancer refers to cancer that has spread from the colon to distant sites in the body. Standard treatment for metastatic colorectal cancer typically includes chemotherapy, which may include the regimens FOLFOX (fluorouracil, Eloxatin®, leucovorin) or FOLFIRI (fluorouracil, Camptosar®, leucovorin). As well, targeted agents such as Avastin or Vectibix may be used to treat the disease. Optimal regimens including chemotherapy and targeted agents are still being evaluated in attempts to extend survival and improve overall outcomes for patients with this disease.

Researchers involved in the Vectibix advanced colorectal cancer evaluation (PACCE) trial recently conducted a clinical trial to evaluate the effectiveness of the addition of Vectibix to Avastin plus chemotherapy. This trial included 800 patients with metastatic colorectal cancer who had not received prior therapy. All patients were treated with Avastin plus chemotherapy (either FOLFOX or FOLFIRI, based on physician choice); one group also received Vectibix.

  • Anticancer responses occurred in 41% of patients treated with Avastin/chemotherapy compared with 39% for those treated with Vectibix/Avastin/chemotherapy.
  • Median progression-free survival was 10.5 months for patients treated with Avastin/chemotherapy compared with 8.8 months for those treated with Vectibix/Avastin/chemotherapy.
  • Median survival had not yet been reached at the time of these trial results for patients treated with Avastin/chemotherapy; median survival was 18.6 months for those treated with Vectibix/Avastin/chemotherapy.
  • Diarrhea, dehydration, and infection rates were higher among the group of patients treated with the addition of Vectibix.

The researchers concluded that the addition of Vectibix to Avastin plus chemotherapy does not appear to improve outcomes for patients with metastatic colorectal cancer compared with Avastin/chemotherapy alone. Further data including molecular analysis may help to identify a potential subgroup of patients who may benefit from the addition of Vectibix.

Reference: Hecht J, Chidiac T, Mitchell, E. et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (BEV) in metastatic colorectal cancer (MCRC). Proceedings of the 9th World Congress on Gastrointestinal Cancer in Barcelona, Spain. 2007; Abstract # 33.

Copyright © 2018 CancerConnect. All Rights Reserved.